Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0462 • ACR Convergence 2021
Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
Eva-Maria Bachmair¹, Kathryn Martin Remmes¹, Lorna Aucott¹, Emma Dures², Richard Emsley³, Stuart Gray⁴, Elizabeth Kidd⁵, Vinod Kumar⁶, Karina Lovell⁷, Graeme MacLennan¹, Paul McNamee¹, John Norrie⁸, Lorna Paul⁹, Jon Packham¹⁰, Stuart Ralston¹¹, Stefan Siebert⁴, Alison Wearden⁷, Gary Macfarlane¹² and Neil Basu⁴, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of West of England, Bristol, United Kingdom, ³King's College London, London, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶NHS Tayside, Dundee, United Kingdom, ⁷University of Manchester, Manchester, United Kingdom, ⁸Usher Institute – University of Edinburgh, Edinburgh, United Kingdom, ⁹Glasgow Caledonian University, Glasgow, Scotland, United Kingdom, ¹⁰Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, United Kingdom, ¹¹University of Edinburgh, Edinburgh, Scotland, United Kingdom, ¹²Epidemiology Group, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, Scotland, United Kingdom
Background/Purpose: Inflammatory rheumatic disease (IRD) related fatigue is pervasive and disabling, even in otherwise stable disease. Although cognitive-behavioural approaches (CBAs) and personalised exercise programmes (PEP)…
Abstract Number: 0568 • ACR Convergence 2021
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Amy Joseph¹, Jodi Yanagida¹, Xinliang Huang¹, Prabha Ranganathan¹, Melissa Laurie², Hong Xian¹ and Seth Eisen¹, ¹VA St. Louis Health Care System, St. Louis, MO, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
Abstract Number: 0590 • ACR Convergence 2021
Association of Lipid Mediator Profiles and Development of Future Incident Inflammatory Arthritis in a High Risk, Anti-citrullinated Protein Antibody Positive Population
Lauren Vanderlinden¹, Elizabeth Bemis², Kristen Polinski³, Kristen Demoruelle⁴, Marie Feser⁵, Jennifer Seifert⁶, Ted Mikuls⁷, Michael Weisman⁸, Jane Buckner⁹, Kevin Deane¹⁰, Michael Clare-Salzler¹¹, V. Michael Holers¹² and Jill Norris¹³, ¹Colorado School of Public Health, Monument, CO, ²Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ³CSPH, Gaithersburg, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵University of Colorado Denver, Aurora, CO, ⁶University of Colorado School of Medicine, Littleton, CO, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰University of Colorado Denver, Denver, CO, ¹¹Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, ¹²University of Colorado, Denver, CO, ¹³Colorado School of Public Health, Aurora, CO
Background/Purpose: Lipid mediators are endogenously derived from the metabolism of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and have important roles in promoting and resolving…
Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Vibeke Strand¹, Anthony Sebba², Savannah Scardo³, Amanda Quebe⁴, Liliana Zaremba-Pechmann⁵ and Peter C Taylor⁶, ¹Stanford University, Portola Valley, CA, ²Division of Rheumatology, University of South Florida, Tampa, FL, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵HaaPACS, Schriesheim, Germany, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
Abstract Number: 0796 • ACR Convergence 2021
Validation of the Simplified Disease Activity Index (SDAI) with a Quick Quantitative C-reactive Protein Assay (SDAI-Q) in Patients with Rheumatoid Arthritis: A National, Multicenter Study
Julia Schally¹, Henning Christian Brandt², Jan Brandt-Jrgens³, Gerd Burmester⁴, Hildrun Haibel⁵, Henriette Käding¹, Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche¹, Mikhail Protopopov⁴, Valeria Rios Rodriguez⁴, Murat Torgutalp⁴, Maryna Verba⁸, Silke Zinke⁹, Denis Poddubnyy¹⁰ and Fabian Proft⁴, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ²Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ³Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin,, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Therapeutic decisions in RA patients should be based on regular disease activity assessment using scores like the Simplified Disease Activity Index (SDAI) or the…
Abstract Number: 0814 • ACR Convergence 2021
Patient Characteristics, Efficacy, and Treatment Patterns of Tofacitinib Monotherapy in Patients with RA: Contextualization of Randomized Controlled Trial Results with Real-world Data
Janet Pope¹, Axel Finckh², Lucia Silva-Fernández³, Peter Mandl⁴, Haiyun Fan⁵, Jose L Rivas⁶, Monica Valderrama⁶ and María Montoro⁶, ¹University of Western Ontario, London, ON, Canada, ²University Hospital of Geneva, Geneve - Vesenaz, Switzerland, ³Hospital Universitari Son Espases, Palma de Mallorca, Spain, ⁴Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer SLU, Madrid, Spain
Background/Purpose: Randomized controlled trials (RCTs) have long been considered the gold standard for clinical research, but can be complemented with real-world data (RWD) to further…
Abstract Number: 0831 • ACR Convergence 2021
Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Years or Older with One or More Cardiovascular Risks: Results from a Phase 3b/4 Randomized Safety Trial
Steven R Ytterberg¹, Deepak L Bhatt², Ted Mikuls³, Gary G Koch⁴, Jose L Rivas⁵, Rebecca Germino⁶, Sujatha Menon⁶, Yanhui Sun⁷, Cunshan Wang⁶, Andrea B Shapiro⁸, Keith S Kanik⁶, Carol A Connell⁶ and Roy Fleischmann⁹, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer CRDC, Shanghai, China (People's Republic), ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: ORAL Surveillance (NCT02092467) was mandated by the US Food and Drug Administration to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based…
Abstract Number: 0946 • ACR Convergence 2021
Distinct Lipidomic Signatures in Synovium and Synovial Fluid of Patients with Rheumatoid Arthritis versus Psoriatic Arthritis
Beatriz Rocha¹, Berta Cillero-Pastor², Anna Illiano³, Valentina Calamia¹, Gabriella Pinto⁴, Angela Amoresano⁴, Cristina Ruiz-Romero⁵, Juan D Cañete⁶, Ron MA Heeren² and Francisco Blanco-García⁷, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006 A Coruña, España., A Coruña, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands., Maastricht, Netherlands, ³CEINGE - Advanced Biotecnology, 80145 Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy., Naples, Italy, ⁴Department of Chemical Sciences, University of Naples “Federico II”, Napoli, Italy. Instituto Nazionale Biostrutture e Biosistemi (INBB), Rome, Italy, ⁵Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain, ⁷Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The differential diagnosis of Rheumatoid Arthritis (RA) and Psoriatic arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of…
Abstract Number: 1015 • ACR Convergence 2021
Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis
Catherine Jagerschmidt¹, Stephanie Lavazais¹, Maikel Colli², Michael Drennan², Erik Verschueren², David Amantini¹, Nicolas Desroy¹ and Steve De Vos², ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Improved management of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) remains an unmet need. Salt-inducible kinases (SIKs) modulate immune cells by a dual mechanism…
Abstract Number: 1127 • ACR Convergence 2021
Synovial Fluid Cytokines, Chemokines, and MMPs in Osteoarthritis Patients with Knee Pain Compared to RA Patients and Normal Knees
Richard Meehan¹, Elizabeth Regan¹, Eric Hoffman¹, Molly Wolff¹, Mary Gill¹, James Crooks², Presant Parmar³, Richard Scheuring⁴, John Hill⁵, karin Pacheco⁶ and Vijaya Knight⁷, ¹National Jewish Health, Denver, CO, ²National Jewsih Health and Colorado School of Public Health, Denver, CO, ³St Joeseph hospital/NJH, Denver, CO, ⁴NASA/JSC, Houston, TX, ⁵University of Colorado Sports Medicine, Denver, CO, ⁶Nationals Jewish Health, Denver, CO, ⁷Children's Hospital Department of Immunology, Denver, CO
Background/Purpose: A major limitation of synovial fluid (SF) biomarker studies in osteoarthritis (OA) has been difficulty in obtaining SF (SF) in patients with small effusions.…
Abstract Number: 1207 • ACR Convergence 2021
A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis
Andrea Hui Ling Low¹, Fang Yi Lim² and Margaret Ma³, ¹National University of Singapore, Singapore, Singapore, ²National Univeristy of Singapore, Singapore, Singapore, ³National University Hospital, Singapore, Singapore
Background/Purpose: Serum Calprotectin level has been shown to correlate with disease activity, ultrasound (US) parameters, treatment response and clinical remission in rheumatoid arthritis (RA). The…
Abstract Number: 1223 • ACR Convergence 2021
A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort
Gerd Burmester¹, Bruno Fautrel², Rieke Alten³, Marco Matucci-Cerinic⁴, Jean hugues Salmon⁵, Thorsten Holzkaemper⁶, Inmaculada de la Torre⁷, Pedro Lopez-Romero⁸, Walid Fakhouri⁸ and Anja Gentzel-Jorczyk⁸, ¹Charité University Medicine Berlin, Berlin, Germany, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³Schlosspark-Klinik University, Berlin, Germany, ⁴University of Florence, Florence, Italy, ⁵Rheumatology, CHU Maison blanche, Reims, Reims, France, ⁶Eli Lilly and Company, Bad Homburg, Germany, ⁷Eli Lilly and Company, Alcobendas, Spain, ⁸Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (BARI) is a JAK1/2 inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) and the treatment of…
Abstract Number: 1239 • ACR Convergence 2021
Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis
Vivian Bykerk¹, Jeffrey Curtis², Paul Emery³, Boulos Haraoui⁴, Elaine Karis⁵, Greg Kricorian⁵, David Collier⁶, Priscilla Yen⁵ and Bradley Stolshek⁵, ¹Hospital for Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ⁴Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen Inc., Simi Valley, CA
Background/Purpose: Patients with RA in remission (REM) may experience disease-worsening (DW) following therapy change or withdrawal. The change in patient-reported outcomes (PROs) after therapy withdrawal…
Abstract Number: 1255 • ACR Convergence 2021
A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months
Stanley Cohen¹, Theodore Mellors², Lixia Zhang³, Alex Jones³, Erin Connolly-Strong⁴, Dimitrios Pappas⁵, Joel Kremer⁶, Johanna Withers³ and Viatcheslav Akmae³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Scipher Medicine, Waltham, TX, ³Scipher Medicine, Waltham, MA, ⁴Scipher Medicine, Austin, TX, ⁵CorEvitas, LLC, Waltham, MA, ⁶Albany Medical College, Latham, NY
Background/Purpose: Most people with rheumatoid arthritis (RA) are prescribed a TNF inhibitor (TNFi) as their first targeted therapy. A blood-based molecular signature response classifier (MSRC)…
Abstract Number: 1515 • ACR Convergence 2021
Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T Cells Are Expanded in Early Rheumatoid Arthritis and Correlate with Response to Treatment
Katie Williams¹, Annabelle Small², Qingxuan Song³, Suzanne Cole⁴, Ling-yang hao⁵, William Murray-Brown⁶, Susanna Proudman⁷, Malcolm Smith⁸, Sunil Nagpal⁹ and Mihir Wechalekar¹⁰, ¹Flinders University, Adelaide, Australia, ²Flinders University, Bedford Park, Australia, ³Janssen Research & Development LLC, Spring House, PA, ⁴Janssen Research, Adelaide, Australia, ⁵Janssen Research, Philadelphia, PA, ⁶GlaxoSmithKline, Adelaide, Australia, ⁷University of Adelaide, Medindie, Australia, ⁸Flinders Medical Centre, Adelaide, Australia, ⁹Janssen Research, Collegeville, PA, ¹⁰Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Programmed death protein 1 (PD-1) expressing T cells, including T follicular and T peripheral helper cells, are expanded in the circulation of individuals with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].